

# Prudent Corporate Advisory

|                 |   |
|-----------------|---|
| Estimate change | ↓ |
| TP change       | ↓ |
| Rating change   | ↔ |

|                       |             |
|-----------------------|-------------|
| Bloomberg             | PRUDENT IN  |
| Equity Shares (m)     | 41          |
| M.Cap.(INRb)/(USDb)   | 94.2 / 1    |
| 52-Week Range (INR)   | 3098 / 1570 |
| 1, 6, 12 Rel. Per (%) | -10/-25/4   |
| 12M Avg Val (INR M)   | 148         |

## Financials & Valuations (INRm)

| Y/E March    | 2026E  | 2027E  | 2028E  |
|--------------|--------|--------|--------|
| Revenues     | 13,186 | 15,779 | 18,787 |
| Opex         | 10,181 | 12,208 | 14,538 |
| PBT          | 3,031  | 3,688  | 4,447  |
| PAT          | 2,255  | 2,744  | 3,308  |
| EPS (INR)    | 54.5   | 66.3   | 79.9   |
| EPS Gr. (%)  | 15.2   | 21.7   | 20.6   |
| BV/Sh. (INR) | 209.7  | 267.0  | 337.9  |

## Ratios (%)

|               |      |      |      |
|---------------|------|------|------|
| EBITDA Margin | 22.8 | 22.6 | 22.6 |
| PAT margin    | 17.1 | 17.4 | 17.6 |
| RoE           | 29.4 | 27.8 | 26.4 |
| Div. Payout   | 11.0 | 13.6 | 11.3 |

## Valuations

|                |      |      |      |
|----------------|------|------|------|
| P/E (x)        | 41.8 | 34.3 | 28.5 |
| P/BV (x)       | 10.8 | 8.5  | 6.7  |
| Div. Yield (%) | 0.3  | 0.4  | 0.4  |

## Shareholding Pattern (%)

| As of    | Dec-25 | Sep-25 | Dec-24 |
|----------|--------|--------|--------|
| Promoter | 55.3   | 55.3   | 55.7   |
| DII      | 22.1   | 21.5   | 23.6   |
| FII      | 16.3   | 16.9   | 14.8   |
| Others   | 6.2    | 6.4    | 5.9    |

FII includes depository receipts

**CMP: INR2,275 TP: INR2,550 (+12%) Neutral**

## Flows momentum strong; TER cut pass through a risk

- Prudent Corporate Advisory (Prudent)'s operating revenue grew 20% YoY/7% QoQ to INR3.4b (in line) in 3QFY26, fueled by a 21% YoY surge in commission and fees income. For 9MFY26, its revenue grew 17% YoY to INR9.6b.
- Operating expenses grew 21% YoY/7% QoQ to INR2.7b (in line); fees and commission expenses rose 20% YoY, employee expenses grew 28% YoY, and other expenses up 20% YoY. EBITDA grew 18% YoY to INR778m (in line), reflecting an EBITDA margin of 22.7% (vs. 23.1% in 3QFY25 and our est. of 22.3%).
- Steady operating performance and higher other income led to a 20% YoY increase in PAT (in line). For 9MFY26, PAT grew 13% YoY to INR1.6b
- The company believes that AMCs will pass on the impact of the 5bp cut in TER, due to the removal of the exit load, to distributors. Consequently, Prudent will also be able to pass this impact on to its distributors.
- We retain our FY26E earnings while reducing our FY27/FY28 estimates by 4%/7% to reflect lower yield assumptions, as we expect that AMCs will pass on the TER cut. We anticipate Prudent to deliver a revenue/EBITDA/PAT CAGR of 19%/17%/19% over FY25-28. We reiterate our Neutral rating with a TP of INR2,550 (based on 32x EPS FY28E).

## QAAUM growth led by robust equity flows

- Prudent's QAAUM grew 21%/7% YoY/QoQ to INR1.3t, with Equity AUM rising 22% YoY, led by record high net sales during the quarter. Monthly SIP flow grew to ~INR11.4b (guidance to be at ~INR12 per month by Mar'26) from INR9.4b in 3QFY25, reflecting a stable market share of ~3.5%.
- Total insurance premium for the quarter came in at INR1.9b (+27% YoY), of which life insurance premium stood at INR1.4b (+25% YoY) and general insurance premium stood at INR501m (+35% YoY).
- Commission and fees income rose 21% YoY to ~INR3.4b, of which INR2.9b (+21% YoY) was contributed by the distribution of MF products, while the contribution from insurance products grew 17% YoY to INR336m.
- Mutual fund revenue, up 8.2% QoQ to INR2.9b, grew faster than the MF QAUM growth of 7.2%. This was led by the INR14m one-off income related to the release of withheld brokerage pertaining to customers whose KYC was pending.
- Revenue from insurance sales grew only 4% QoQ, despite 12% QoQ growth in overall fresh premiums. This was due to the 18% reduction in health insurance commission rates post-GST to nil (effective Oct'25).
- Revenue from the stockbroking segment declined 10% YoY but remained flat QoQ at INR44m. Revenue from other financial and non-financial products rose 21% YoY to INR86m.
- Other income was up 44% YoY/16% QoQ, led by MTM gains on equity-oriented investments and ~7% rise in the Nifty during the quarter.
- Commission & fee expenses grew 20% YoY/6% QoQ to INR2b.

Research Analyst: **Prayesh Jain** (Prayesh.Jain@MotilalOswal.com) / **Nitin Aggarwal** (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: **Kartikaya Mohata** (Kartikaya.Mohata@MotilalOswal.com) / **Muskan Chopra** (Muskan.Chopra@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on [www.motilaloswal.com/Institutional-Equities](http://www.motilaloswal.com/Institutional-Equities), Bloomberg, Thomson Reuters, Factset and S&P Capital.

- Employee costs rose 28% YoY to INR383m (included an INR14.9m one-time labor code impact). ESOP expenses stood at INR16.1m in 3QFY26, and are expected to remain at similar levels over the next three quarters; total annual ESOP charge estimated at INR72m.
- Other expenses were up 20% YoY to INR248m. The CIR came in at 18.4% vs 17.8% in 3QFY25 and 17.9% in 2QFY26.

### Key takeaways from the management commentary

- Management reiterated its confidence in retail momentum, guiding towards INR12b of monthly SIP inflows by Mar'26 (current monthly run-rate at 11.4b).
- Management indicated that no formal discussions with AMCs have taken place yet with regard to passing on the TER cut. Clarity is expected by mid-March, with conversations likely to begin by mid-Feb'26.
- Management remains very optimistic on SIF, which is expected to emerge as a large product category and act as a long-term growth driver.

### Valuation and view

- Prudent continues to deliver strong growth in its mutual fund distribution business, supported by healthy SIP inflows, steady yields, an expanding MFD network, and incremental contributions anticipated from the Indus Capital MF acquisition.
- However, regulatory headwinds remain a near-term concern — including the draft proposals on TER rationalization for AMCs and potential GST exemption implications on insurance, wherein life insurers have been able to pass on only 10% impact, while health insurers have passed on ~100% of the impact. While these factors may exert some short-term pressure on earnings, Prudent is expected to partially pass on the impact to distributors on a proportionate basis.
- **We retain our FY26E earnings while reducing our FY27/FY28 estimates by 4%/7% to reflect lower yield assumptions, as we expect that AMCs will pass on the TER cut. We anticipate Prudent to deliver a revenue/EBITDA/PAT CAGR of 19%/17%/ 19% over FY25-28. We reiterate our Neutral rating with a TP of INR2,550 (based on 32x EPS FY28E).**

## Quarterly performance

(INR m)

| Y/E March                                  | FY25         |              |              |              | FY26         |              |              |              | FY25          | FY26E         | 3QFY26E      | Act x/t Est. (%) | YoY        | QoQ       |
|--------------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|---------------|--------------|------------------|------------|-----------|
|                                            | 1Q           | 2Q           | 3Q           | 4Q           | 1Q           | 2Q           | 3Q           | 4QE          |               |               |              |                  |            |           |
| Commission and Fees Income                 | 2,477        | 2,845        | 2,827        | 2,809        | 2,910        | 3,168        | 3,407        | 3,589        | 10,960        | 13,072        | 3,341        | 2.0              | 21%        | 8%        |
| Other Operating revenue                    | 17           | 15           | 23           | 20           | 28           | 30           | 25           | 32           | 76            | 114           | 28           | -11.6            | 6%         | -17%      |
| <b>Revenue from Operations</b>             | <b>2,494</b> | <b>2,861</b> | <b>2,850</b> | <b>2,829</b> | <b>2,938</b> | <b>3,198</b> | <b>3,432</b> | <b>3,621</b> | <b>11,036</b> | <b>13,186</b> | <b>3,369</b> | <b>1.9</b>       | <b>20%</b> | <b>7%</b> |
| Change YoY (%)                             | 50.8         | 50.5         | 35.8         | 18.0         | 17.8         | 11.8         | 20.4         | 28.0         | 37.1          | 19.5          | 18.2         |                  |            |           |
| Operating Expenses                         | 1,904        | 2,174        | 2,191        | 2,143        | 2,265        | 2,476        | 2,654        | 2,786        | 8,412         | 10,181        | 2,618        | 1.4              | 21%        | 7%        |
| Change YoY (%)                             | 50.8         | 48.0         | 37.0         | 19.8         | 18.9         | 13.9         | 21.1         | 30.0         | 37.5          | 21.0          | 19.5         |                  |            |           |
| <b>EBIDTA</b>                              | <b>590</b>   | <b>687</b>   | <b>659</b>   | <b>686</b>   | <b>673</b>   | <b>722</b>   | <b>778</b>   | <b>834</b>   | <b>2,624</b>  | <b>3,004</b>  | <b>751</b>   | <b>3.6</b>       | <b>18%</b> | <b>8%</b> |
| Depreciation                               | 62.9         | 67.2         | 73.7         | 74.8         | 72.5         | 76.8         | 80.2         | 79.7         | 279           | 309           | 77           | 4.2              | 9%         | 4%        |
| Finance Cost                               | 4.9          | 5.7          | 6.4          | 6.7          | 6.9          | 7.3          | 16.9         | 6.8          | 24            | 38            | 7            | 142.0            | 166%       | 132%      |
| Other Income                               | 70           | 78           | 66           | 85           | 103          | 82           | 95           | 95           | 299           | 374           | 110          | -13.5            | 44%        | 16%       |
| <b>PBT</b>                                 | <b>592</b>   | <b>693</b>   | <b>645</b>   | <b>690</b>   | <b>696</b>   | <b>719</b>   | <b>776</b>   | <b>843</b>   | <b>2,621</b>  | <b>3,031</b>  | <b>777</b>   | <b>-0.1</b>      | <b>20%</b> | <b>8%</b> |
| Change YoY (%)                             | 57.9         | 70.6         | 34.7         | 15.4         | 17.5         | 3.8          | 20.3         | 22.2         | 41.1          | 15.7          | 20.5         |                  |            |           |
| Tax Provisions                             | 149.9        | 177.9        | 163.1        | 173.5        | 178.1        | 184.0        | 199.7        | 214.3        | 664           | 776           | 199          | 0.4              | 22%        | 9%        |
| <b>Net Profit</b>                          | <b>442</b>   | <b>515</b>   | <b>482</b>   | <b>516</b>   | <b>518</b>   | <b>535</b>   | <b>576</b>   | <b>628</b>   | <b>1,957</b>  | <b>2,255</b>  | <b>578</b>   | <b>-0.3</b>      | <b>20%</b> | <b>8%</b> |
| Change YoY (%)                             | 58.3         | 69.2         | 35.0         | 15.9         | 17.1         | 4.0          | 19.6         | 21.7         | 41.0          | 15.3          | 20.0         |                  |            |           |
| <b>Key Operating Parameters (%)</b>        |              |              |              |              |              |              |              |              |               |               |              |                  |            |           |
| EBIDTA Margin                              | 23.6         | 24.0         | 23.1         | 24.3         | 22.9         | 22.6         | 22.7         | 23.0         | 23.8          | 22.8          | 22.3         | 38bp             | -46bp      | 10bp      |
| Cost to Income Ratio (Ex-sharing)          | 19.5         | 18.9         | 17.8         | 17.6         | 18.2         | 17.9         | 18.4         | 17.9         | 18.4          | 18.1          | 18.5         | -15bp            | 61bp       | 48bp      |
| PBT Margin                                 | 23.7         | 24.2         | 22.6         | 24.4         | 23.7         | 22.5         | 22.6         | 23.3         | 23.7          | 23.0          | 23.1         | -45bp            | -2bp       | 11bp      |
| Tax Rate                                   | 25.3         | 25.7         | 25.3         | 25.2         | 25.6         | 25.6         | 25.7         | 25.4         | 25.3          | 25.6          | 25.6         | 13bp             | 44bp       | 16bp      |
| PAT Margins                                | 17.7         | 18.0         | 16.9         | 18.2         | 17.6         | 16.7         | 16.8         | 17.4         | 17.7          | 17.1          | 17.2         | -37bp            | -11bp      | 5bp       |
| MF revenue / QAAUM (bps)                   | 91.9         | 91.8         | 91.8         | 90.3         | 90.3         | 91.3         | 92.2         | 92.0         | 91.3          | 91.4          | 91.0         | 116bp            |            |           |
| <b>Revenue from Operations (INR Mn)</b>    |              |              |              |              |              |              |              |              |               |               |              |                  |            |           |
| <b>Commission and Fees Income</b>          |              |              |              |              |              |              |              |              |               |               |              |                  |            |           |
| Distribution of MF Products-Trail Revenue  | 2,052        | 2,343        | 2,421        | 2,297        | 2,489        | 2,716        | 2,940        | 2,974        | 9,113         | 11,119        | 2,842        | 3.4              | 21%        | 8%        |
| Distribution of Insurance Products         | 261          | 339          | 286          | 402          | 291          | 324          | 336          | 472          | 1,288         | 1,423         | 358          | -6.0             | 17%        | 4%        |
| Stock Broking and Allied Services          | 77           | 73           | 49           | 41           | 50           | 44           | 44           | 50           | 240           | 188           | 46           | -4.3             | -10%       | 0%        |
| Other Financial and Non-Financial Products | 87           | 90           | 71           | 69           | 80           | 83           | 86           | 93           | 317           | 342           | 95           | -9.5             | 21%        | 4%        |
| <b>Revenue from Operations Mix (%)</b>     |              |              |              |              |              |              |              |              |               |               |              |                  |            |           |
| As % of Commission and Fees Income         |              |              |              |              |              |              |              |              |               |               |              |                  |            |           |
| Distribution of MF Products-Trail Revenue  | 82.3         | 81.9         | 84.9         | 81.2         | 84.7         | 84.9         | 85.7         | 82.1         | 82.6          | 84.3          | 84.4         | 130bp            | 73bp       | 74bp      |
| Distribution of Insurance Products         | 10.5         | 11.9         | 10.0         | 14.2         | 9.9          | 10.1         | 9.8          | 13.0         | 11.7          | 10.8          | 10.6         | -82bp            | -24bp      | -34bp     |
| Stock Broking and Allied Services          | 3.1          | 2.6          | 1.7          | 1.4          | 1.7          | 1.4          | 1.3          | 1.4          | 2.2           | 1.4           | 1.4          | -8bp             | -44bp      | -9bp      |
| Other Financial and Non-Financial Products | 3.5          | 3.1          | 2.5          | 2.4          | 2.7          | 2.6          | 2.5          | 2.6          | 2.9           | 2.6           | 2.8          | -31bp            | 1bp        | -9bp      |
| <b>Opex Mix (%)</b>                        |              |              |              |              |              |              |              |              |               |               |              |                  |            |           |
| Fees and commission                        | 74.4         | 75.1         | 76.9         | 76.8         | 76.4         | 76.9         | 76.2         | 0.0          | 75.8          | 76.6          |              |                  | -65bp      | -65bp     |
| Employees expenses                         | 14.2         | 13.6         | 13.7         | 11.3         | 13.9         | 13.3         | 14.4         | 0.0          | 13.2          | 13.7          |              |                  | 74bp       | 111bp     |
| Other expenses                             | 11.3         | 11.3         | 9.5          | 11.9         | 9.7          | 9.8          | 9.4          | 0.0          | 11.0          | 9.7           |              |                  | -9bp       | -46bp     |



## Key takeaways from the management commentary

### Business Highlights

- Despite a range-bound equity market, equity-oriented AUM grew 22.4% YoY, driven by strong net inflows and also supported by the Indus Capital acquisition.
- Top 5 AMCs contribute ~50% of the overall AUM of the company as of Dec'25.
- Management reiterated confidence in retail momentum, guiding towards INR12b of monthly SIP inflows by Mar'26 (current monthly run-rate at 11.35b).
- The reported MFD market share decline is largely due to the Indus Capital AUM mix; on an underlying basis, market share has actually improved over the past one year.

- Client churn, which was elevated last year, has normalized and is now in line with long-term averages.
- The company has transitioned from traditional insurance products (high-yield driven) to term and ULIP products (comparatively lower yields), i.e., Tulip products. This renewed focus has led to a marginal moderation in overall yields.
- Management indicated that no formal discussions with AMCs have taken place yet with regard to passing on of the TER cut. Clarity is expected by mid-March, with conversations likely to begin by mid-Feb.
- The broking business has been merged with Prudent Corporate, and management expects it to contribute more meaningfully to the overall revenue mix over time.
- Management remains very optimistic on SIF, which is expected to emerge as a large product category and act as a long-term growth driver.
- Total employee count stood at 1,539 as of Dec'25.


#### **GST Impact on the Insurance segment**

- GST impact in the life insurance segment reduced sharply from ~30% in Oct'25 to ~10% currently, and is expected to continue until Mar'26, driven by a shift in business mix, while in the general insurance segment, the impact remained at 100%.


#### **Financials**

- PAT increased 19.6% YoY, driven by steady operating performance and higher other income.
- Other income rose QoQ, aided by MTM gains on equity-oriented investments and ~7% rise in the Nifty during the quarter.
- Mutual fund revenues up 8.2% QoQ grew faster than the MF QAUM growth of 7.2%, led by recording of INR14m (one-off related to release of withheld brokerage, KYC related). The core yields remained stable QoQ and over 9MFY26, excluding these one-offs.
- Insurance revenue grew 4% QoQ despite overall fresh premium rising 12% QoQ (led by 19% QoQ growth in Life insurance premium) impacted by 18% reduction in health insurance commission rates post GST reduction to nil (effective Oct'25).
- Employee costs included INR14.9m, reflecting one-time labor code impact.
- ESOP expenses were INR16.1m in 3QFY26, expected to remain at similar levels over the next three quarters; total annual ESOP charge estimated at INR72m.
- Finance costs increased 2.7x YoY due to interest accretion on deferred consideration payable for the INDUS Capital acquisition. Guided for this cost to continue for the next 11 quarters.
- Depreciation increased during the quarter following a revision in useful life of assets to 15 years from currently 10 years (till Nov'36).
- Treasury corpus stood at INR5.4b, providing capacity for future opportunities.


## Story in charts

**Exhibit 1: Trend in QAAUM growth**



Source: Company, MOFSL

**Exhibit 2: Share of Equity AUM remained stable**



Source: Company, MOFSL

**Exhibit 3: Monthly SIP flows on an upward trajectory**



Source: Company, MOFSL

**Exhibit 4: Trend in equity gross SIP flows**



Source: Company, MOFSL

**Exhibit 5: Revenue stood at INR3.4b in 3QFY26**



Source: MOFSL, Company

**Exhibit 6: Trend in other income**



Source: MOFSL, Company

**Exhibit 7: C/I ratio (%) trend**



Source: MOFSL, Company

**Exhibit 8: Trend in EBITDA (INRm) and EBITDA margins (%)**



Source: MOFSL, Company

**Exhibit 9: PAT margin stood at 17% in 3QFY26**



Source: MOFSL, Company

**Exhibit 10: Premium mix (%)**


Source: MOFSL, Company

**Exhibit 11: MFD trends**


Source: MOFSL, Company

**Exhibit 12: One-year forward P/E**


Source: MOFSL, Company

## Financials and valuations

| Income Statement               |              |              |              |              |              |               | (INR m)       |               |               |
|--------------------------------|--------------|--------------|--------------|--------------|--------------|---------------|---------------|---------------|---------------|
| Y/E March                      | 2020         | 2021         | 2022         | 2023         | 2024         | 2025          | 2026E         | 2027E         | 2028E         |
| Commission and Fees Income     | 2,293        | 2,776        | 4,428        | 6,048        | 7,990        | 10,960        | 13,072        | 15,654        | 18,649        |
| Other Operating income         | 55           | 89           | 80           | 65           | 60           | 76            | 114           | 125           | 138           |
| <b>Revenue From Operations</b> | <b>2,348</b> | <b>2,865</b> | <b>4,508</b> | <b>6,113</b> | <b>8,050</b> | <b>11,036</b> | <b>13,186</b> | <b>15,779</b> | <b>18,787</b> |
| Change (%)                     | 5.8          | 22.0         | 57.3         | 35.6         | 31.7         | 37.1          | 19.5          | 19.7          | 19.1          |
| Commission and Fees expenses   | 1,205        | 1,531        | 2,464        | 3,252        | 4,354        | 6,380         | 7,795         | 9,348         | 11,150        |
| Employee benefits expense      | 489          | 555          | 693          | 833          | 928          | 1,109         | 1,398         | 1,677         | 1,979         |
| Impairment of FI               | 12           | 20           | -1           | -20          | 0            | 0             | 0             | 0             | 0             |
| Other expenses                 | 176          | 140          | 199          | 295          | 837          | 922           | 989           | 1,183         | 1,409         |
| <b>Operating Expenses</b>      | <b>1,882</b> | <b>2,246</b> | <b>3,355</b> | <b>4,359</b> | <b>6,119</b> | <b>8,412</b>  | <b>10,181</b> | <b>12,208</b> | <b>14,538</b> |
| Change (%)                     | 2.4          | 19.4         | 49.4         | 29.9         | 40.4         | 37.5          | 21.0          | 19.9          | 19.1          |
| <b>Operating Profit</b>        | <b>467</b>   | <b>619</b>   | <b>1,153</b> | <b>1,754</b> | 1,931        | 2,624         | 3,004         | 3,570         | 4,249         |
| Other Income                   | 14           | 84           | 78           | 75           | 196          | 299           | 374           | 494           | 606           |
| Depreciation                   | 79           | 81           | 134          | 240          | 248          | 279           | 309           | 334           | 361           |
| Finance Cost                   | 27           | 17           | 26           | 21           | 21           | 24            | 38            | 42            | 48            |
| Exceptional items              | 0            | 0            | 0            | 0            | 0            | 0             | 0             | 0             | 0             |
| <b>Profit Before Tax</b>       | <b>374</b>   | <b>605</b>   | <b>1,071</b> | <b>1,568</b> | <b>1,858</b> | <b>2,621</b>  | <b>3,031</b>  | <b>3,688</b>  | <b>4,447</b>  |
| Change (%)                     | 30.6         | 61.7         | 77.0         | 46.4         | 18.5         | 41.1          | 15.6          | 21.7          | 20.6          |
| Tax                            | 96           | 152          | 268          | 401          | 471          | 664           | 776           | 944           | 1,138         |
| Tax Rate (%)                   | 25.6         | 25.2         | 25.0         | 25.6         | 25.3         | 25.3          | 25.6          | 25.6          | 25.6          |
| <b>PAT</b>                     | <b>279</b>   | <b>453</b>   | <b>803</b>   | <b>1,167</b> | <b>1,387</b> | <b>1,957</b>  | <b>2,255</b>  | <b>2,744</b>  | <b>3,308</b>  |
| Change (%)                     | 32.5         | 62.6         | 77.4         | 45.2         | 18.9         | 41.1          | 15.2          | 21.7          | 20.6          |
| Dividend                       | 5            | 5            | 41           | 62           | 83           | 104           | 248           | 373           | 373           |

### Balance Sheet

| Y/E March                | 2020         | 2021         | 2022         | 2023         | 2024         | 2025         | 2026E         | 2027E         | 2028E         |
|--------------------------|--------------|--------------|--------------|--------------|--------------|--------------|---------------|---------------|---------------|
| Equity Share Capital     | 10           | 10           | 207          | 207          | 207          | 207          | 207           | 207           | 207           |
| Reserves & Surplus       | 1,115        | 1,566        | 2,169        | 3,293        | 4,607        | 6,470        | 8,477         | 10,848        | 13,784        |
| <b>Net Worth</b>         | <b>1,125</b> | <b>1,576</b> | <b>2,376</b> | <b>3,500</b> | <b>4,814</b> | <b>6,677</b> | <b>8,684</b>  | <b>11,055</b> | <b>13,991</b> |
| Borrowings               | 78           | 26           | 0            | 0            | 0            | 0            | 0             | 0             | 0             |
| Other Liabilities        | 758          | 1,247        | 1,624        | 1,699        | 2,762        | 2,760        | 2,898         | 3,043         | 3,195         |
| <b>Total Liabilities</b> | <b>1,961</b> | <b>2,850</b> | <b>4,000</b> | <b>5,199</b> | <b>7,576</b> | <b>9,437</b> | <b>11,581</b> | <b>14,098</b> | <b>17,186</b> |
| Cash and Investments     | 1,035        | 1,598        | 967          | 2,127        | 3,780        | 5,436        | 6,910         | 8,319         | 9,906         |
| Change (%)               | 41.4         | 54.4         | -39.5        | 120.0        | 77.7         | 43.8         | 27.1          | 20.4          | 19.1          |
| Loans                    | 9            | 5            | 7            | 9            | 10           | 11           | 13            | 14            | 15            |
| Net Fixed Assets         | 179          | 166          | 157          | 148          | 163          | 303          | 349           | 401           | 501           |
| Current Assets           | 737          | 1,080        | 2,870        | 2,915        | 3,622        | 3,686        | 4,311         | 5,364         | 6,763         |
| <b>Total Assets</b>      | <b>1,961</b> | <b>2,850</b> | <b>4,000</b> | <b>5,199</b> | <b>7,576</b> | <b>9,437</b> | <b>11,581</b> | <b>14,098</b> | <b>17,186</b> |

E: MOFSL Estimates



## Financials and valuations

### Cash Flow

| INR m                              | 2020 | 2021  | 2022   | 2023   | 2024   | 2025   | 2026E  | 2027E  | 2028E  |
|------------------------------------|------|-------|--------|--------|--------|--------|--------|--------|--------|
| PAT                                | 279  | 453   | 803    | 1,167  | 1,387  | 1,957  | 2,255  | 2,744  | 3,308  |
| Change in Accumulated Depreciation | 79   | 81    | 134    | 240    | 248    | 279    | 309    | 334    | 361    |
| Change in Reserves                 | 21   | 3     | 38     | 19     | 9      | 10     | 0      | 0      | 0      |
| Finance cost                       | 27   | 17    | 26     | 21     | 21     | 24     | 38     | 42     | 48     |
| Other Income                       | -14  | -84   | -78    | -75    | -196   | -299   | -374   | -494   | -606   |
| Change in Working Capital          | 173  | 143   | 45     | -110   | 207    | -220   | -458   | -840   | -1,159 |
| Cashflow from Operation            | 565  | 614   | 968    | 1,261  | 1,676  | 1,750  | 1,770  | 1,786  | 1,952  |
| Other Income                       | 14   | 84    | 78     | 75     | 196    | 299    | 374    | 494    | 606    |
| Change in Investments              | 6    | -140  | -188   | -1,040 | -1,031 | -1,194 | -1,827 | -1,097 | -1,645 |
| Change in Loans                    | -129 | -46   | 6      | 38     | 33     | 102    | 15     | 16     | 17     |
| Change in Fixed Asset              | -111 | -71   | -1,614 | -137   | -139   | -367   | -399   | -471   | -566   |
| Cashflow from Investing            | -220 | -172  | -1,718 | -1,064 | -941   | -1,160 | -1,836 | -1,057 | -1,588 |
| Interest Expense                   | -27  | -17   | -26    | -21    | -21    | -24    | -38    | -42    | -48    |
| Dividend Expense                   | -5   | -5    | -41    | -62    | -83    | -104   | -248   | -373   | -373   |
| Cashflow from Financing            | -32  | -22   | -67    | -83    | -104   | -127   | -286   | -415   | -420   |
| Net Cashflow                       | 313  | 419   | -818   | 123    | 622    | 463    | -352   | 314    | -57    |
| Opening Cash                       | 660  | 973   | 1,392  | 575    | 698    | 1,320  | 1,783  | 1,431  | 1,745  |
| Closing Cash                       | 973  | 1,392 | 575    | 698    | 1,320  | 1,783  | 1,431  | 1,745  | 1,688  |

### Ratios

| Y/E March                       | 2020        | 2021        | 2022        | 2023        | 2024        | 2025        | 2026E       | 2027E       | 2028E       |
|---------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| As a percentage of Revenues     |             |             |             |             |             |             |             |             |             |
| Commission and Fees Income      | 97.6        | 96.9        | 98.2        | 98.9        | 99.3        | 99.3        | 99.1        | 99.2        | 99.3        |
| Other Operating income          | 2.4         | 3.1         | 1.8         | 1.1         | 0.7         | 0.7         | 0.9         | 0.8         | 0.7         |
| <b>Total cost</b>               | <b>80.1</b> | <b>78.4</b> | <b>74.4</b> | <b>71.3</b> | <b>76.0</b> | <b>76.2</b> | <b>77.2</b> | <b>77.4</b> | <b>77.4</b> |
| Commission and Fees expenses    | 51.3        | 53.4        | 54.7        | 53.2        | 54.1        | 57.8        | 59.1        | 59.2        | 59.4        |
| Employee Cost                   | 20.8        | 19.4        | 15.4        | 13.6        | 11.5        | 10.1        | 10.6        | 10.6        | 10.5        |
| Other Opex Cost                 | 8.0         | 5.6         | 4.4         | 4.5         | 10.4        | 8.4         | 7.5         | 7.5         | 7.5         |
| <b>PBT</b>                      | <b>15.9</b> | <b>21.1</b> | <b>23.8</b> | <b>25.7</b> | <b>23.1</b> | <b>23.8</b> | <b>23.0</b> | <b>23.4</b> | <b>23.7</b> |
| <b>PAT</b>                      | <b>11.9</b> | <b>15.8</b> | <b>17.8</b> | <b>19.1</b> | <b>17.2</b> | <b>17.7</b> | <b>17.1</b> | <b>17.4</b> | <b>17.6</b> |
| <b>Profitability Ratios (%)</b> |             |             |             |             |             |             |             |             |             |
| RoE                             | 28.5        | 33.5        | 40.7        | 39.7        | 33.4        | 34.1        | 29.4        | 27.8        | 26.4        |
| Dividend Payout Ratio           | 37.1        | 22.8        | 5.1         | 5.3         | 6.0         | 5.3         | 11.0        | 13.6        | 11.3        |

| Valuations         | 2020         | 2021         | 2022         | 2023        | 2024        | 2025        | 2026E       | 2027E       | 2028E       |
|--------------------|--------------|--------------|--------------|-------------|-------------|-------------|-------------|-------------|-------------|
| BVPS (INR)         | 27.2         | 38.1         | 57.4         | 84.5        | 116.3       | 161.3       | 209.7       | 267.0       | 337.9       |
| Price-BV (x)       | <b>83.7</b>  | <b>59.8</b>  | <b>39.6</b>  | <b>26.9</b> | <b>19.6</b> | <b>14.1</b> | <b>10.8</b> | <b>8.5</b>  | <b>6.7</b>  |
| EPS (INR)          | 6.7          | 11.0         | 19.4         | 28.2        | 33.5        | 47.3        | 54.5        | 66.3        | 79.9        |
| Change (%)         | 32.7         | 62.6         | 77.2         | 45.1        | 18.9        | 41.1        | 15.2        | 21.7        | 20.6        |
| Price-Earnings (x) | <b>337.5</b> | <b>207.6</b> | <b>117.1</b> | <b>80.7</b> | <b>67.9</b> | <b>48.1</b> | <b>41.8</b> | <b>34.3</b> | <b>28.5</b> |
| DPS (INR)          | 2.5          | 2.5          | 1.0          | 1.5         | 2.0         | 2.5         | 6.0         | 9.0         | 9.0         |
| Dividend Yield (%) | <b>0.1</b>   | <b>0.1</b>   | <b>0.0</b>   | <b>0.1</b>  | <b>0.1</b>  | <b>0.1</b>  | <b>0.3</b>  | <b>0.4</b>  | <b>0.4</b>  |

E: MOSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



| Explanation of Investment Rating |                                                                                              |
|----------------------------------|----------------------------------------------------------------------------------------------|
| Investment Rating                | Expected return (over 12-month)                                                              |
| BUY                              | $\geq 15\%$                                                                                  |
| SELL                             | $< -10\%$                                                                                    |
| NEUTRAL                          | $-10\% \text{ to } 15\%$                                                                     |
| UNDER REVIEW                     | Rating may undergo a change                                                                  |
| NOT RATED                        | We have forward looking estimates for the stock but we refrain from assigning recommendation |

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on [www.motilaloswal.com](http://www.motilaloswal.com) > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

#### Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, it does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

| Contact Person        | Contact No.                 | Email ID                     |
|-----------------------|-----------------------------|------------------------------|
| Ms. Hemangi Date      | 022 40548000 / 022 67490600 | query@motilaloswal.com       |
| Ms. Kumud Upadhyay    | 022 40548082                | servicehead@motilaloswal.com |
| Mr. Ajay Menon        | 022 40548083                | am@motilaloswal.com          |
| Mr. Neeraj Agarwal    | 022 40548085                | na@motilaloswal.com          |
| Mr. Siddhartha Khemka | 022 50362452                | po.research@motilaloswal.com |

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.